NASDAQ:ZGNXZogenix Stock Price, Forecast & News

Zogenix's stock was trading at $22.69 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, ZGNX stock has increased by 9.1% and is now trading at $24.76.
View which stocks have been most impacted by COVID-19.

11 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Zogenix in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Zogenix.

Zogenix is scheduled to release its next quarterly earnings announcement on Thursday, November 5th 2020.
View our earnings forecast for Zogenix.

Zogenix, Inc. (NASDAQ:ZGNX) posted its earnings results on Wednesday, August, 5th. The company reported ($0.96) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($1.02) by $0.06. The firm earned $1.03 million during the quarter, compared to analyst estimates of $1.10 million. Zogenix had a negative net margin of 8,758.48% and a negative return on equity of 57.75%.
View Zogenix's earnings history.

11 equities research analysts have issued 12 month price objectives for Zogenix's stock. Their forecasts range from $27.00 to $78.00. On average, they anticipate Zogenix's share price to reach $55.22 in the next twelve months. This suggests a possible upside of 123.0% from the stock's current price.
View analysts' price targets for Zogenix.

News headlines about ZGNX stock have been trending negative recently, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to five, with scores nearest to five being the most favorable. Zogenix earned a news impact score of -2.4 on InfoTrie's scale. They also assigned media headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the near future.
View the latest news about Zogenix.

Zogenix saw a increase in short interest in the month of February. As of February 15th, there was short interest totaling 7,130,000 shares, an increase of 16.3% from the January 31st total of 6,130,000 shares. Based on an average daily volume of 875,700 shares, the short-interest ratio is presently 8.1 days.
View Zogenix's Short Interest.

Some companies that are related to Zogenix include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Zogenix investors own include GW Pharmaceuticals PLC- (GWPH), Vanda Pharmaceuticals (VNDA), Gilead Sciences (GILD), AbbVie (ABBV), Canopy Growth (CGC), QUALCOMM (QCOM), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD), Southwest Airlines (LUV) and NVIDIA (NVDA).

Zogenix trades on the NASDAQ under the ticker symbol "ZGNX."

Zogenix's stock is owned by many different retail and institutional investors. Top institutional investors include Federated Hermes Inc. (3.86%), Bank of New York Mellon Corp (2.60%), FMR LLC (2.02%), Candriam Luxembourg S.C.A. (1.71%), Cadian Capital Management LP (1.60%) and Emerald Advisers LLC (1.13%). Company insiders that own Zogenix stock include Ashish M Sagrolikar, Cam L Garner, Erle T Mast, Gail M Farfel, James B Breitmeyer, Mark C Wiggins, Michael P Smith, Renee P Tannenbaum, Roger Hawley and Stephen J Farr.
View institutional ownership trends for Zogenix.

ZGNX stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, International Biotechnology Trust PLC, Bailard Inc., WINTON GROUP Ltd, Oak Ridge Investments LLC, Premier Asset Management LLC, Ensign Peak Advisors Inc, and GW&K Investment Management LLC. Company insiders that have sold Zogenix company stock in the last year include Gail M Farfel, James B Breitmeyer, Michael P Smith, and Stephen J Farr.
View insider buying and selling activity for Zogenix.

ZGNX stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Cadian Capital Management LP, Bank of New York Mellon Corp, Marshall Wace LLP, Emerald Advisers LLC, Emerald Mutual Fund Advisers Trust, Marshall Wace North America L.P., and Federated Hermes Inc.. Company insiders that have bought Zogenix stock in the last two years include Ashish M Sagrolikar, Cam L Garner, and Mark C Wiggins.
View insider buying and selling activity for Zogenix.

Shares of ZGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of ZGNX stock can currently be purchased for approximately $24.76.

Zogenix has a market capitalization of $1.37 billion and generates $3.65 million in revenue each year. The company earns $-419,500,000.00 in net income (profit) each year or ($3.90) on an earnings per share basis. Zogenix employs 90 workers across the globe.

The official website for Zogenix is www.zogenix.com.

Zogenix's mailing address is 5959 Horton Street Suite 500, EMERYVILLE CA, 94608. The company can be reached via phone at 510-550-8300 or via email at [email protected]